The strategic review and deep workforce cut indicate the company is running out of cash before FDA approval on vCLAS. The lowered conversion price on the 13% notes will almost certainly trigger conversion, diluting common equity severely. Watch for a distressed sale or reverse merger announcement in the coming weeks.
Price Chart
Executive Summary
Adagio Medical is laying off 58% of its workforce (25 of 43 employees) and initiating a formal strategic alternatives review, including a potential sale or merger. The company also lowered the conversion price on its 13% Senior Secured Convertible Notes to 85% of the 5-day VWAP through October 31, 2026, which will likely trigger massive dilution if noteholders convert. With only ~$7.7M in cash as of June 30, 2026, and a pending PMA for its vCLAS system, the restructuring signals a cash crunch and a high probability of a distressed sale or equity wipeout.
Key Facts
- Workforce reduction of 25 out of 43 full-time employees (58% cut), effective September 23, 2026
- Estimated $1.3 million in cash severance and related costs
- Board initiated formal process to explore strategic alternatives including acquisition, merger, or business combination
- Conversion price on 13% Senior Secured Convertible Notes lowered to 85% of the lowest 5-day VWAP through October 31, 2026
- Preliminary unaudited cash, cash equivalents and marketable securities of approximately $7.7 million as of June 30, 2026
- PMA application for vCLAS Ventricular Ablation System submitted to FDA in May 2026
Financial Impact
$1.3 million in cash restructuring costs; ~$7.7M cash runway being consumed; conversion price reset to 85% of VWAP will likely trigger heavy dilution for noteholders
Risk Factors
- Massive dilution from note conversion at 85% of VWAP through October 31, 2026
- Cash runway of ~$7.7M likely insufficient to fund operations through FDA decision without a transaction
- Potential for no viable strategic alternative, leading to bankruptcy or liquidation
- PMA approval for vCLAS is binary and uncertain; failure would eliminate the primary asset value
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-109821 |
| Document: adgm-20260923xex99.htm | 0001104659-26-109821 |
| Document: 0001104659-26-109821-index-headers.html | 0001104659-26-109821 |
| Document: 0001104659-26-109821-index.html | 0001104659-26-109821 |
| Document: 0001104659-26-109821.txt | 0001104659-26-109821 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | DEF 14A | $0.1253 $0.1208 | ▼ −3.59% | ▼ −2.44% | $0.1011 (−19.31%) |
Oct 1, 2026 25d ago | 8-K | $0.1531 $0.1300 | ▲ +15.09% | ▲ +16.25% | $0.1011 (+33.96%) |
Sep 23, 2026 4w ago | 8-K | $0.2280 $0.1530 | ▲ +32.89% | ▲ +32.22% | $0.1011 (+55.66%) |
Aug 11, 2026 11w ago | 8-K | $0.7190 $0.6460 | ▲ +10.15% | ▲ +9.75% | $0.1011 (+85.94%) |
Jul 13, 2026 15w ago | 10-K/A | $0.5710 $0.5300 | ▼ −7.18% | ▼ −6.40% | $0.1011 (−82.29%) |
May 21, 2026 22w ago | 8-K | $0.8410 $0.7699 | ▼ −8.45% | ▼ −10.13% | $0.1011 (−87.98%) |
May 12, 2026 24w ago | 8-K | $0.9230 $0.8830 | ▼ −4.33% | ▼ −4.41% | $0.1011 (−89.05%) |
Apr 27, 2026 26w ago | 8-K | $1.15 $0.9410 | ▼ −18.17% | ▼ −18.57% | $0.1011 (−91.21%) |
Apr 8, 2026 28w ago | 8-K | $1.41 $1.43 | ▲ +1.42% | ▼ −2.10% | $0.1011 (−92.83%) |
Apr 6, 2026 29w ago | EFFECT | $1.25 $1.33 | ▼ −6.40% | ▼ −2.27% | $0.1011 (+91.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers